NEWAMSTERDAM PHARMA CO NV
NAMSNASDAQTrading Snapshot
- Day Range
- $27.53 β $27.82
- 52-Week Range
- $23.05 β $42.21
- Volume
- $1.75B
- Avg Volume
- $1.50B
- Shares Outstanding
- 116.9M
- Next Earnings
- Oct 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $4M
- P/E Ratio
- β
- P/S Ratio
- 469.7x
- EPS (TTM)
- $-2.15
- Dividend Yield
- β
Why Investors Own NAMS
- βHigh-growth profile β revenue up +41.6% YoY with expanding US Equity exposure.
- βHealthy economics β 67% gross margin and 29% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NEWAMSTERDAM PHARMA CO NV
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerβs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day August 5, 2026 9:00 AM EDTCompany ParticipantsMatthew Philippe - Executive VP & Head of...
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day - Slideshow
2026-08-05. The following slide deck was published by NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses of $(0.15) per share
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or βNewAmsterdamβ or the βCompanyβ), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (βCVDβ) with elevated low-density lipoprotein cholesterol (βLDL-Cβ), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analy
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill
NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovascular risk beyond LDL-C. Key catalysts into 2026Γ’ΒΒ27; valuation execution risk.